0
Akari Therapeutics Plc Banner Image

Akari Therapeutics Plc has reached its limit for free report views

Work for Akari Therapeutics Plc? Upgrade Your Profile and unlock all your annual reports.

Akari Therapeutics Plc

  • Ticker AKTX
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Akari Therapeutics Plc Logo Image
  • 1-10 Employees
  • Based in London, England
Akari is a biopharmaceutical company focused on developing inhibitors of acute and chronic inflammation, specifically for the treatment of rare and orphan diseases, in particular those where the complement (C5) or leukotriene (LTB4) systems, or both complement and leukotrienes together, play a primary role in disease progression. Akari's lead drug candidate, nomacopan (formerly known asMore Coversin), is a C5 complement inhibitor that also independently and specifically inhibits leukotriene B4 (LTB4) activity. Nomacopan is currently being clinically evaluated in four target indications: bullous pemphigoid (BP), atopic keratoconjunctivitis (AKC), thrombotic microangiopathy (TMA), as well as COVID-19 pneumonia and related COVID diseases. Akari believes that the dual action of nomacopan on both C5 and LTB4 may be beneficial in AKC, BP and COVID-19 pneumonia. Akari is also developing other tick derived proteins, including longer acting versions.
Akari Therapeutics Plc

Most Recent Annual Report

Akari Therapeutics Plc MOST RECENT 2019 Annual Report

Report Locked. Akari Therapeutics Plc has reached its limit for free report views.

Older/Archived Annual Reports